Tag: Regulatory

REYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 22,666,667 of its ordinary shares at an offering price of $3.75 per share. All ordinary shares to be sold in the Offering will be offered by Alvotech. The Offering is expected to close on or about June 17, 2026, subject to satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up to an additional 3,400,000 ordinary shares at the public offering price, less underwriting discounts and commissions. Before deducting the underwriting discounts and commissions and offering expenses, the Company expects to receive total gross proceeds of approximately $85 million from the Offering, or approximately $98 million if the underwriters exercise in full their option to purchase additional shares.

MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye diseaseAt 450 mg Q4W, MHB018A achieved a remarkable 81% proptosis response at...

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”), of the important June 23, 2026 lead plaintiff deadline.

DERM Zero is a world-first - using Class III regulated medical device1 technology to deliver autonomous clinical grade skin cancer assessments from a standard...

Terra Innovatum Global N.V. (NASDAQ: NKLR) Files 2025 Form 10‑k and Reports Fourth Quarter and Fiscal Year 2025 Financial Results

VANCOUVER, British Columbia, June 15, 2026 (GLOBE NEWSWIRE) -- Central 1 Credit Union (Central 1) today announced that on June 30, 2026 it will redeem at par all of its issued and outstanding Series 7 Subordinated Notes due on June 30, 2031 (the Notes).

STAMFORD, Conn., June 15, 2026 (GLOBE NEWSWIRE) -- The Lovesac Co. (NASDAQ: LOVE), the Designed for Life home and technology brand best known for its Sactionals, The World's Most Adaptable Couch, today announced it has appointed Andrew Farag as the Company’s Executive Vice President, Chief Financial Officer and Treasurer, effective immediately. He succeeds Keith Siegner who has stepped down from the role but will remain with the Company for a short period to support the transition.

Transaction expands and diversifies portfolio, immediately boosts cash flow

Transaction expands and diversifies portfolio, immediately boosts cash flow

In the news release, Kootenay Silver Announces Positive PEA with a US$763 Million After-Tax NPV & 41% IRR for La Cigarra Silver Project, issued...

According to a new report by Grand View Research, Global Managed Services Market Expected to Grow at a CAGR of 9.9% Through 2033 as...

SHERIDAN, Wyo., June 15, 2026 /PRNewswire/ -- The global laboratory filtration market is projected to grow from USD 4.5 billion in 2025 to USD...

ST. JOHN'S, NL, June 15, 2026 /CNW/ - Aurion Resources Ltd. (TSXV: AU) (OTCQX: AIRRF) ("Aurion") is pleased to announce the successful completion of the previously...